Sight Sciences (SGHT) Set to Announce Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) is set to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Sight Sciences has set its FY 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.13. The company had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $18.70 million. Sight Sciences had a negative net margin of 68.53% and a negative return on equity of 41.94%. During the same quarter in the previous year, the company posted ($0.35) EPS. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Stock Performance

NASDAQ SGHT opened at $5.82 on Tuesday. Sight Sciences has a 1 year low of $1.04 and a 1 year high of $11.20. The business’s fifty day moving average is $5.00 and its two-hundred day moving average is $4.14. The company has a quick ratio of 12.65, a current ratio of 13.29 and a debt-to-equity ratio of 0.26.

Insider Transactions at Sight Sciences

In related news, CFO Alison Bauerlein sold 10,123 shares of the company’s stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $51,424.84. Following the completion of the sale, the chief financial officer now owns 426,248 shares in the company, valued at approximately $2,165,339.84. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Paul Badawi sold 12,571 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $63,860.68. Following the completion of the sale, the chief executive officer now owns 5,750,729 shares of the company’s stock, valued at $29,213,703.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Alison Bauerlein sold 10,123 shares of the company’s stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $51,424.84. Following the transaction, the chief financial officer now directly owns 426,248 shares in the company, valued at $2,165,339.84. The disclosure for this sale can be found here. Insiders have sold a total of 34,129 shares of company stock valued at $173,375 over the last ninety days. Corporate insiders own 27.10% of the company’s stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC restated a “hold” rating on shares of Sight Sciences in a report on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $4.60.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.